Moreover, these data indicate that HSP90 inhibitors such as PU-H71, currently under clinical evaluation in patients, synergize at subliminal doses with cold plasma treatment toward impaired tumor cell viability. This evidence concerns the gene HSP90AB1 and neoplasm.